Prime Medicine Inc Revenue Growth Rates (PRME), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Prime Medicine Inc   (NASDAQ: PRME)
 

PRME's Revenue Growth by Quarter and Year

Prime Medicine Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRME Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.15
1st Quarter March 0.86
FY 2.01





PRME Revenue second quarter 2026 Y/Y Growth Comment
Prime Medicine Inc reported Revenue growth of 3.04% year on year in the second quarter 2026, to $ 1.15 millions, this is lower than Prime Medicine Inc 's recent average Revenue surge of 106.58%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Revenue growth. While Prime Medicine Inc ' s Revenue increase of 3.04% ranks overall at the positon no. 2514 in the second quarter 2026.


PRME Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -61.47 % - -
3rd Quarter September - 485.71 % - -
2nd Quarter June 3.04 % - - -
1st Quarter March -40.69 % 145.76 % - -
FY   - 55.7 % - -

Financial Statements
Prime Medicine Inc 's second quarter 2026 Revenue $ 1.15 millions PRME's Income Statement
Prime Medicine Inc 's second quarter 2025 Revenue $ 1.12 millions Quarterly PRME's Income Statement


PRME Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -31.71 % 938.1 % -
3rd Quarter September - 9.82 % - -
2nd Quarter June 34.19 % -22.76 % - -
1st Quarter March 2.38 % -33.49 % - -
FY (Year on Year)   - 55.7 % - -


Back to PRME Growth rate Comparisons >> Back to PRME Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #362
Overall #2514

Revenue Y/Y Growth Statistics
High Average Low
486.12 % 106.58 % -61.61 %
(Jun 30 2026)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #42
Healthcare Sector #362
Overall #2514
Revenue Y/Y Growth Statistics
High Average Low
486.12 % 106.58 % -61.61 %
(Jun 30 2026)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Prime Medicine Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
944.5 % 100.38 % -100 %
(Dec 31 2024)  


PRME's II. Quarter Q/Q Revenue Comment
Prime Medicine Inc achieved in the II. Quarter 2026 below company average Revenue jump of 34.19% quarter on quarter, to $ 1.15 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -22.76% growth in the II. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Prime Medicine Inc 's Revenue growth quarter on quarter, overall rank is 338.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #79
Overall #338
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #79
Overall #338
Revenue Q/Q Growth Statistics
High Average Low
944.5 % 100.38 % -100 %
(Dec 31 2024)  


PRME's II. Quarter Q/Q Revenue Comment
Prime Medicine Inc achieved in the II. Quarter 2026 below company average Revenue jump of 34.19% quarter on quarter, to $ 1.15 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -22.76% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Prime Medicine Inc 's Revenue growth quarter on quarter, overall rank is 338.


Prime Medicine Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 4.07 $ 4.03 $ 4.63 $ 5.98 $ 4.96
Y / Y Revenue Growth (TTM) -17.9 % - - - -
Year on Year Revenue Growth Overall Ranking # 3388 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 0.97 % -12.91 % -22.5 % 20.48 % -
Seq. Revenue Growth (TTM) Overall Ranking # 849 # 694 # 602 # 555 # 0


Cumulative Revenue growth Comment
Prime Medicine Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Prime Medicine Inc 's annual Revenue increase would be -17.9% year on year to $4 millions.

In the Healthcare sector 452 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3388.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 453
Overall # 3388

Revenue TTM Y/Y Growth Statistics
High Average Low
-17.9 %
 -17.9 %
-17.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 175
S&P 500 # 849
Cumulative Revenue growth Comment
Prime Medicine Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Prime Medicine Inc 's annual Revenue fall would be -17.9% year on year to $4 millions.

In the Healthcare sector 452 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3388.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 27
Healthcare Sector # 453
Overall # 3388

Revenue TTM Y/Y Growth Statistics
High Average Low
-17.9 %
-17.9 %
-17.9 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 27
Sector # 175
S&P 500 # 849




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PRME's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bruker Corporation5.22%$ 5.220 millions
Davita Inc 5.17%$ 5.165 millions
Park Dental Partners Inc 5.10%$ 5.102 millions
Lumexa Imaging Holdings Inc 5.08%$ 5.076 millions
Merck and Co Inc 5.07%$ 5.068 millions
Cv Sciences Inc 4.96%$ 4.958 millions
Viatris Inc 4.88%$ 4.877 millions
Fulgent Genetics Inc 4.86%$ 4.855 millions
Zimmer Biomet Holdings Inc 4.80%$ 4.799 millions
Mettler toledo International Inc 4.48%$ 4.485 millions
Phibro Animal Health Corporation4.40%$ 4.405 millions
Align Technology inc 4.35%$ 4.355 millions
Opko Health Inc 4.32%$ 4.319 millions
Dariohealth Corp 4.29%$ 4.291 millions
Orthofix Medical Inc 4.15%$ 4.147 millions
Pediatrix Medical Group Inc 4.04%$ 4.040 millions
Nrc Health3.98%$ 3.978 millions
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions


About Prime Medicine Inc Revenue Growth Rates (PRME), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Prime Medicine Inc (CIK 1894562).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-053883
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Prime Medicine Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.